TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Nov 30, 2020 14:04 JST
Source:
Eisai
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
A total of 43 poster presentations regarding perampanel are planned, including analysis results from the phase III clinical trial (FREEDOM/Study 342), which evaluated the effectiveness and safety of the perampanel monotherapy in the open-label extension (52 weeks) for epilepsy patients with partial onset seizures (POS) from 12 to 74 years of age without prior treatment history. Additionally, results from the phase III clinical trial Study 311 evaluating safety and tolerability of perampanel as an adjunctive therapy in pediatric epilepsy patients with POS or primary generalized tonic clonic (PGTC) seizures from 4 to less than 12 years of age will be presented.
Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. In Japan and the United States, perampanel is currently approved for monotherapy and adjunctive use in the treatment of POS (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older, as well as adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Eisai considers neurology, including epilepsy, a therapeutic area of focus. As we provide perampanel globally, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.
For more information, visit
https://www.eisai.com/news/2020/pdf/enews202080pdf.pdf
.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
More Press release >>
Latest Press Release
Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput
Nov 01, 2025 00:45 JST
Sharp to Introduce AQUOS sense10 Smartphone
Nov 01, 2025 00:27 JST
Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform
Nov 01, 2025 00:07 JST
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 09:30 JST
MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Oct 30, 2025 23:14 JST
NEC and e& Sign MoU to Drive Joint Sustainability Initiatives
Oct 30, 2025 22:46 JST
MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market
Oct 30, 2025 22:19 JST
Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America
Oct 30, 2025 21:40 JST
MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa
Oct 30, 2025 17:58 JST
DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025
Oct 30, 2025 17:29 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 14:43 JST
Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025
Oct 30, 2025 14:33 JST
Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 30, 2025 14:26 JST
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
Oct 30, 2025 14:18 JST
Overview of Honda CEO Speech at the Japan Mobility Show 2025
Oct 30, 2025 14:00 JST
Honda Presents World Premiere of the Prototype of Honda 0 a, new SUV Model for Honda 0 Series at Japan Mobility Show 2025
Oct 30, 2025 11:55 JST
Honda Presents World Premiere of Super-ONE Prototype Compact EV at Japan Mobility Show 2025
Oct 30, 2025 11:50 JST
Mitsubishi Motors Debuts Mitsubishi Elevance Concept and Adventure-Inspiring Lineup at Japan Mobility Show 2025
Oct 30, 2025 11:39 JST
Fujitsu and PwC Japan partner on economic security measures for sovereign cloud solution
Oct 30, 2025 11:22 JST
Hitachi Rail becomes world's first transportation firm to adopt new NVIDIA IGX Thor solution for real-time AI
Oct 30, 2025 11:00 JST
More Latest Release >>